
Expanded Access Study for Renal Transplant Patients With Envarsus XR ™
Renal FailureOpen label, multi-center, expanded access study for renal transplant patients with once daily Envarsus XR (Tacrolimus).

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung...
Non-small Cell Lung CancerLung Cancer2 moreThe purpose of this study is to provide brigatinib for those patients with locally advanced and/or metastatic patients with ALK+ NSCLC on an expanded access basis due to their inability to meet eligibility criteria for on-going recruiting trials, inability to participate in other clinical trials (e.g., poor performance status, lack of geographic proximity), or because other medical interventions are not considered appropriate or acceptable.

Expanded Access to VAL-083
CancerThis is an expanded access program (EAP) for eligible participants. This program is designed to provide access to VAL-083 (dianhydrogalactitol) prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Margetuximab Expanded Access Program
HER2-positive Breast CancerHER2-positive CarcinomaThe purpose of the Expanded Access program is to provide margetuximab to patients with pretreated HER2+ breast cancer for whom potential benefit justifies potential treatment risks.

Expanded Access to ABT-414
Glioblastoma or Solid TumorsEpidermal Growth Factor Receptor (EGFR) DiagnosisThis is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABT-414 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas
GlioblastomaGlioma of BrainIPILIMUMAB Extended Access Program for patients who received chemotherapy and / or radiation therapy before the protocol, before or after the operation.

AMG 714 Expanded Access Program
Celiac DiseaseExpanded access requests for AMG 714 may be considered for adult patients with biopsy proven Refractory Celiac Disease Type II who have failed all available treatment options and do not have EATL. To request access, use Responsible Party contact information provided in this record.

An Expanded Access Program for AM0010 (Pegilodecakin)
MelanomaProstate Cancer7 moreThis is an Expanded Access Program (EAP) available to patients who have advanced cancers, who have failed or progressed on standard of care systemic therapy and do not qualify for ongoing clinical trials.

Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects...
Crohn's DiseaseProtocol 620 provides PROCHYMAL(R) adult human mesenchymal cells to specifically chosen Crohn's disease patients at participating centers who typically have already demonstrated good response in another PROCHYMAL study, are not eligible for other PROCHYMAL studies, and in the view of the investigator, would not benefit significantly from other Crohn's therapies but would benefit from use of PROCHYMAL. The study is not placebo-controlled or randomized.

Emergency Use of OCR-002 in Acute Liver Failure (ALF)
Acute Liver FailureThis study provides emergency use of the unapproved study medication in ALF patients with acute liver failure who are not responding to standard of care.